

#5
YC
4/15/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614
Examiner : William R A Jarvis
Applicant(s) : BHF Wong, et al.
Serial Number : 10/035,100
Filed : December 28, 2001
For : New Drug Combination

RECEIVED
APR 11 2003
TECH CENTER 1600/2900

Commissioner of Patents and Trademarks
Washington, DC 20231

ELECTION OF SPECIES PURSUANT TO 37 CFR 1.143

Sir:

This is a response to the Office Communication mailed March 26, 2003.

STATUS OF CLAIMS

Claims 1-22 are pending in the application, and are subject to a restriction or election requirement.

The Office finds that the claims are generic to a plurality of disclosed patentably distinct species comprising (a) one or more norepinephrine inhibitors and (b) one or more neuroleptic agents.


ELECTION

Applicants elect reboxetine from group (a) and clozapine from group (b). Structures are provided on the attached Exhibit as requested by the Office.

INVENTORSHIP

No change in inventorship is necessitated by reason of this election.

Respectfully submitted,



Stephen L. Nesbitt, Attorney
Registration No. 28,981

Date: April 4, 2003


Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (616) 833-1837 or (616) 833-9500
Telefax o. (616) 833-8897 or (616) 833-2316




Exhibit

RECEIVED
APR 11 2003
TECH CENTER 1600/2900



Reboxetine



Clozapine